16:27 EST UroGen Pharma (URGN) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
- UroGen Pharma reports Q3 EPS (69c), consensus (68c)
- UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
- UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
- UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment